



Review

Oxygen Therapy: Systems and Indications in the Pediatric and Adult Population

Cristina García-Muro^{a,*}, **Moisés Alejandro Alatorre-Jiménez^b**, **Vickramjeet Johal^b**, **Alejandro Marín-Medina^c**, **Ramandeep Kaur^b**, **Eduardo Esteban-Zubero^d**

^aDepartment of Pediatrics, Hospital San Pedro, Logroño, Spain

^bDepartment of Pediatrics, SUNY Downstate Medical Center, Brooklyn, NY, USA

^cDepartment of Molecular Biology and Genomics, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara, Jalisco, México

^dEmergency Department, Hospital San Pedro, Logroño, Spain

ARTICLE INFO

Article history:

Received 15 March 2020

Received in revised form 22 March 2020

Accepted 6 April 2020

Keywords:

Respiratory insufficiency

Oxygen therapy

High flow oxygen therapy

ABSTRACT

Hypoxemia is defined as the decrease in arterial partial pressure of oxygen (PaO₂) below 80 mmHg. One of the ways to alleviate this condition is through oxygen therapy, which consists of administering oxygen at a concentration higher than atmospheric. This therapy is indicated in various pathologies and is aimed to treat hypoxemia and reduce the patient's myocardial demand and respiratory effort. Classically, this treatment has been carried out using low-flow systems, in which the inspiratory fraction of oxygen (FiO₂) cannot be regulated. However, an increase in the use of high-flow oxygen therapy (HFO) has been observed in recent years. These systems allow for greater patient comfort as well as more precise regulation of the FiO₂.

The purpose of this article is to review respiratory physiology to understand respiratory failure from a clinical and pathophysiological point of view. Likewise, the different oxygen therapy systems most widely used are discussed, as well as their indications for acute and chronic pathologies, both in the pediatric and adult populations.

© 2020 The Authors. Published by Iberoamerican Journal of Medicine. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. INTRODUCTION

Oxygen therapy consists of administering oxygen at a higher concentration than atmospheric. These concentration values are directly proportional to the altitude. Its indications are varied, having an essential role in both acute and chronic pathologies. The main objectives of oxygen therapy are: a) to treat and/or prevent hypoxemia; b) to decrease myocardial demand; c) to

decrease respiratory effort, and d) to treat pulmonary hypertension [1]. Likewise, it is important to define several concepts to know their indications. The arterial partial pressure of oxygen (PaO₂) is the amount of dissolved oxygen in the blood. Its normal values are between 70-90 mmHg, PaO₂ is related to alveolar ventilation, ventilation/perfusion ratio, and the fraction of oxygen in the inspired air (FiO₂). Normal PaO₂ values are approximately equivalent to arterial oxygen saturation (SatO₂), which is defined as the arterial fraction of

* Corresponding author.

E-mail address: cgmuro@riojasalud.es

© 2020 The Authors. Published by Iberoamerican Journal of Medicine. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

<http://doi.org/10.5281/zenodo.3949857>

hemoglobin bound to oxygen [1], of 95-100%.

Once these basic concepts have been defined, it is necessary to clarify the difference between hypoxemia and hypoxia. Hypoxemia is defined as the decrease in PaO₂ below 80 mmHg. On the other hand, hypoxia is described as a decrease in tissue oxygenation [2]. Considering PaO₂ values, different levels of hypoxemia can be defined, as shown in Table 1.

Table 1. Classification of oxemia according to PaO₂ y SatO₂

Oxygenation	PaO ₂ (mmHg)	SatO ₂ (%)
Hyperoxia	> 90	100
Normal	70-90	95-100
Acceptable hypoxemia	60-70	90-95
Critical hypoxemia	40-60	85-90
Severe hypoxemia	< 40	< 80

PaO₂: Arterial partial pressure of oxygen; SatO₂: Arterial oxygen saturation.

2. RESPIRATORY PHYSIOLOGY

The primary function of the lung parenchyma is to supply oxygen to the arterial blood and to remove carbon dioxide from the mixed venous blood of the pulmonary artery produced by cellular metabolism and gas exchange [3]. PaO₂ determines arterial oxygenation, while PaCO₂ (arterial partial pressure of carbon dioxide) indicates carbon dioxide levels dissolved in the arteries (34-38 mmHg under standard conditions). Adequate gas exchange is measured by several factors, including control of ventilation (V), alveolar ventilation (V_A), alveolar-capillary diffusion, and pulmonary perfusion (Q) [4]. The deterioration of any of them or the incorrect coordination between them will determine respiratory failure situations with or without hypercapnia [5].

In each respiratory cycle, approximately 500 ml are mobilized, the inspired volume being slightly higher (1%) than the exhaled volume due to the amount of oxygen being inhaled is greater than the carbon dioxide that is exhaled. When talking about ventilation, the effective measure is V_A, since V also encompasses the dead space

(DV) [6]. The dead space is the anatomical (trachea and large airways) and the alveolar dead space, which increases with age. The DV represents 1/3 of the total V [5, 6].

After ventilation, gas exchange occurs; this is determined by alveolar-capillary diffusion [7], which is based on a pressure system that mobilizes air from the areas of higher pressure to those of lower pressure. Gas diffusion depends on several factors:

1. The distance to be traveled by gas molecules
2. The exchange surface
3. The partial pressure of the gas on each side of the interface (pressure gradient)
4. Gas diffusibility [8]

Once the gas exchange has been carried out, the O₂ and CO₂ are dissolved in the plasma or bound to hemoglobin [9]. Under normal conditions, pulmonary O₂ transfer is limited by perfusion, and only in very particular situations (such as extreme exercise) is this transfer limited by diffusion [10]. V_A and Q are higher at the bases than at the vertices. In addition, the V_A/Q gradient differs according to anatomical location, being higher at the vertices (> 3) than at the bases (< 1). This gradient is because the V_A is much higher than Q at the vertices [11]. An important concept is the arterial alveolus difference or gradient of O₂ (AaPO₂), which is understood as the difference between P_AO₂ and PaO₂. Its levels reflect the efficiency of the lung as a gas exchanger, orienting us on the possible mechanism of alterations in gas exchange [12].

3. HYPOXEMIA AND RESPIRATORY INSUFFICIENCY

Hypoxemia (PaO₂ < 70 mmHg) and respiratory failure may be due to various mechanics with different clinical significance (Table 2) [13]. The onset of respiratory failure may be acute or chronic, and the appearance of compensation mechanisms is possible if the onset is carried out more gradually [13]. The diagnosis of respiratory failure is made by arterial blood gas and, according to CO₂ levels, it is classified as type I (without hypercapnia) or type II (with hypercapnia) (Table 3) [14].

Mechanism	PaO ₂	PaCO ₂	AaPO ₂	Response to O ₂	Causes
↓FiO ₂	↓	↓	Normal	Yes	Altitude
Hypoventilación	↓	↑↑	Normal	Yes	Obstructive or restrictive respiratory failure Central or peripheral respiratory failure with dead space increase
↓ diffusion	↓	Normal/↓	↑	Yes	ARDS Pulmonary edema Interstitial diseases
Disturbance on V/Q Mismatch	↓	↓/↑	↑	Yes	Pneumonia Pneumothorax Atelectasis Pulmonary edema Asthma
Shunting	↓	↓	↑	No/low	Congenital heart disease

PaO₂: Arterial partial pressure of oxygen; AaPO₂: Arterial alveolus difference or gradient of O₂; FiO₂: Fraction of inspired oxygen in the air; V/Q: Ventilation/perfusion ratio. ARDS: Adult respiratory distress syndrome.

Type I	<u>Pathological lung</u> : COPD, diffuse interstitial lung disease, severe asthma, vascular lung disease, cardiogenic pulmonary edema, ARDS.
Type II	<u>Healthy lung</u> : Neuromuscular disease, rib cage disease, neurological disease, CNS depressant drugs. <u>Pathological lung</u> : COPD, bronchiectasis, diffuse interstitial lung disease

COPD: Chronic obstructive pulmonary disease; ARDS: Adult respiratory distress syndrome; CNS: Central nervous system.

4. HYPOXIA CLINICAL MANIFESTATIONS

Hypoxia symptoms are nonspecific and related to the causative disease and the levels of oxygen and carbon dioxide. Therefore cases of sudden onset hypoxemia produce more significant symptomatology since compensation mechanisms are not generated [15]. Among the clinical manifestations is an increase in respiratory effort, peripheral cyanosis, and neurological involvement, which varies from lack of concentration and apathy (chronic onset) to clouding and stupor (acute symptoms) [16]. Furthermore, hypercapnia causes disorientation, motor agitation, facial diaphoresis, headache, clouding, and even coma in the abrupt symptoms, whereas, in the most chronic symptoms, only mild drowsiness. [17]. Table 4 lists the most characteristic clinical signs.

As we have already mentioned, in chronic hypoxia symptoms, compensation mechanisms are generated. These are based on the increase in heart rate and cardiac output, thus improving the V/Q ratio through an improved blood flow through pulmonary vasculature [18]. On the other hand, an increase in the renal secretion of erythropoietin causes polycythemia that increases the oxygen-carrying capacity of the blood [19]. However, these mechanisms are harmful in the medium-long term, since pulmonary vasoconstriction generates irreversible anatomical

alterations such as hypertrophy of the middle muscular layer of the pulmonary arterioles and fibrosis of the intima, which leads to pulmonary hypertension and right heart failure [20]. All this is favored by the increase in cardiac output and polycythemia, producing an elevation in myocardial demand and higher energy consumption, which can cause a malnutrition status that favors the appearance of some general manifestations [21].

Hypoxemia	Dyspnea, tachypnea, thoracoabdominal incoordination, cyanosis, tachycardia, arterial hypertension, agitation, paradoxical pulse, hypotension (late stages) and bradycardia (late stages).
Hypercapnia	Disorientation, clouding, flapping, tachycardia, high blood pressure, hypotension (late stages), and bradycardia (late stages)

5. INDICATIONS AND BENEFITS OF OXYGEN THERAPY

Primary objective of oxygen therapy is the prevention or reversal of the consequences of hypoxemia, ultimately improving tissue oxygenation. Over time, several studies have been carried out to verify its benefits in different pathologies, highlighting studies in chronic obstructive pulmonary disease (COPD) [22, 23]. Both studies established that mortality decreased when giving oxygen for 15 hours a day compared to not giving it for that period. It further decreased when applying a continuous regimen of 17.7 hours/day. Based on these results, the criteria for the indication of continuous home oxygen therapy were defined; based on: PaO₂ < 55 mmHg, or between 55 and 60 mmHg with the presence of peripheral edema, cor pulmonale, hematocrit values above 55%, stocks of cardiac arrhythmias and mental or central nervous system disorders that could be attributed to hypoxemia [24].

Table 5. Subsidiary pathologies of chronic home oxygen therapy

ADULT POPULATION
<u>Obstructive pulmonary diseases</u> : Chronic obstructive pulmonary disease, cystic fibrosis, bronchiectatic diseases, asthma.
<u>Lung diseases related to sleep</u> : Obstructive sleep apnea-hypopnea syndrome.
<u>Restrictive lung diseases</u> : Diffuse interstitial lung disease, idiopathic pulmonary fibrosis, pulmonary hypertension.
<u>Non-pulmonary pathologies</u> : heart failure, cluster headache, hepatopulmonary syndrome.
<u>Palliative care</u>
PEDIATRIC POPULATION
<u>Intrinsic parenchymal involvement</u> : Neonatal chronic lung disease, pulmonary hypoplasia, congenital diaphragmatic hernia, interstitial lung diseases, idiopathic pulmonary fibrosis, advanced cystic fibrosis, bronchiolitis obliterans, bronchiectasis.
<u>Restrictive lung disease</u> : Neuromuscular diseases, diseases of the chest wall.
<u>Upper airway obstruction</u>
<u>Primary or secondary pulmonary hypertension to lung disease</u>
<u>Heart disease with pulmonary hypertension</u>
<u>Palliative care</u>

In the presence of these results, the use of oxygen therapy has spread to other pathologies that present with chronic respiratory failure with a pattern similar to COPD. However, no improvement in survival has been observed in patients with idiopathic pulmonary fibrosis [25], pulmonary hypertension [26], cystic fibrosis [27], or heart failure [28]. Despite this, it is recommended to consider oxygen therapy in these entities in the presence of severe hypoxemia ($\text{PaO}_2 < 60$ mmHg).

Taking into account this point of general indication, we can assess acute or chronic situations in need of treatment with oxygen therapy. Among the acute situations, the most recognizable are the situations of arterial hypoxemia, imbalances in the V/Q, short-circuits or right-left shunts, and decreased FiO_2 in ambient air (high altitudes). Likewise, other symptoms are observed where there may be a $\text{PaO}_2 > 60$ mmHg with a significant deterioration of the tissue supply, such as in situations of low expenditure secondary to cardiogenic shock, in acute anemia or carbon monoxide poisoning (competes in binding to hemoglobin) [29, 30].

The chronic use of oxygen therapy differs depending on whether the pediatric or adult population is involved. It should be noted that childhood pathologies are different, and it may be necessary to use it temporarily, although, if needed, it is required both at home and when traveling. Its indication is related to development, which is why its prognosis is better than in adulthood. In addition, it may be necessary only for night-time use, a different criterion than that of the adult population (> 15 h daily) [29, 31]. Table 5 summarizes the most prevalent pathologies in adults and pediatric populations in which chronic oxygen therapy is indicated.

6. OXYGEN THERAPY SYSTEMS

The different oxygen administration formats are classified according to the flow that reaches the patient, differentiating high and low flow systems [32].

Low flow systems are characterized by not supplying all the air required by the inspiratory flow demand, which is why the use of ambient air, in addition to the air provided by the system, is required to satisfy this need [33]. Within this group, we find nasal goggles, simple masks, and reservoir masks (Figure 1). The most important feature of these systems is that they do not ensure stable levels of FiO_2 , achieving variable oxygen concentrations in the inspired air depending on the flow of oxygen supplied and the ventilatory pattern of each patient (Table 6) [34].

On the other hand, high flow systems provide the patient with inspiratory flows higher than their peak demand; that is, the system provides all the inspired air. In this way, they allow us to keep FiO_2 constant independently of the patient's ventilatory pattern. Within this group are the Venturi mask and high flow oxygen therapy systems and active humidification [33, 35] (Figure 1).

Table 6. Low and high flow oxygen delivery systems

System	Flow (l/m)	FiO_2
Nasal goggles	1	0.24
	2	0.28
	3	0.32
	4	0.36
	5	0.40
	6	0.44
Simple masks	5-6	0.40
	6-7	0.50
	7-8	0.60
Reservoir mask with rebreathing	10-15	0.60-0.80
Reservoir mask without rebreathing	10-15	> 0.80
Venturi mask	4	0.24
	6	0.28
	8	0.31
	10	0.35
	12	0.40
	15	0.50

FiO_2 : Fraction of inspired oxygen in the air.

7. HIGH FLOW OXYGEN THERAPY (HFO)

High flow oxygen therapy systems provides to the patient an adjustable air and oxygen mixture. It is a system with increasing use in recent years due to its excellent tolerance and ease of use. It consists on the administration of high oxygen flows through nasal cannulas. To promote tolerance in patients, this air is administered humidified (humidity between 95-100%) and hot (34-40 °C). The benefits of this system are due to the humidification and temperature of the gas itself, which reduces metabolic expenditure, improves compliance and lung elasticity, and




Figure 1: Oxygen therapy systems low flow systems like reservoir masks (A), nasal goggles (B) as well as high flow systems (Venturi mask, C).

facilitates tolerance and comfort. Furthermore, other advantages of these systems are that they decrease the nasopharyngeal dead space, decrease the inspiratory resistance and provide a certain degree of pulmonary distension pressure (CPAP), which is neither measurable nor adjustable, but which has numerous benefits (decreases atelectasis, improves the V/Q ratio and in premature patients reduces apnea).

According to age, the limits that define high-flow oxygen therapy are 1-8 lpm in newborns, in children 1-2 lpm/kg, and more than 30 lpm in adults [33]. The indications for this system have increased in recent years, being accepted generically in cases of moderate acute respiratory failure or in cases of hypoxemia that do not respond to conventional oxygen treatment. Table 7 shows pathologies in children and adults in which the HFO has shown utility.

Contraindications are few, limited to anatomical causes (nasal obstruction or choanal atresia, trauma or surgery in the nasopharynx, etc.) or severe respiratory failure requiring mechanical ventilation. Caution is also recommended in the use of this type of system in cases of hypoxemia with hypercapnia since the use of oxygen may cancel the respiratory stimulus generated by hypoxia [33].

Table 7. Subsidiary pathologies of high flow oxygen therapy

ADULT POPULATION

Hypoxemic acute respiratory failure
 Acute heart failure
 Acute hypercapnic respiratory failure
 Post-intubation, pre-intubation failure
 Bronchoscopy and other invasive procedures
 Palliative care
 Chronic respiratory diseases
 Severe acute respiratory infections

PEDIATRIC POPULATION

Acute respiratory failure secondary to bronchiolitis, asthma, and pneumonia
 Congestive heart failure
 Neonatal respiratory distress (prevention and treatment)
 Post-intubation respiratory support
 Postoperative of cardiovascular surgery
 Non-invasive mechanical ventilation withdrawal
 Neuromuscular pathology
 Apnea of prematurity
 Upper airway obstruction
 Post-intubation laryngitis
 Sleep apnea-hypopnea syndrome

8. REFERENCES

1. Walsh BK, Smallwood CD. *Pediatric Oxygen Therapy: A Review and Update*. *Respir Care*. 2017;62(6):645-61. doi: 10.4187/respcare.05245.
2. Bach J. *A Quick Reference on Hypoxemia*. *Vet Clin North Am Small Anim Pract*. 2017;47(2):175-9. doi: 10.1016/j.cvsm.2016.10.004.
3. Sharma G, Goodwin J. *Effect of aging on respiratory system physiology and immunology*. *Clin Interv Aging*. 2006;1(3):253-60. doi: 10.2147/cia.2006.1.3.253.
4. Baumgardner JE, Hedenstierna G. *Ventilation/perfusion distributions revisited*. *Curr Opin Anaesthesiol*. 2016;29(1):2-7. doi: 10.1097/ACO.0000000000000269.
5. Vo P, Kharasch VS. *Respiratory failure*. *Pediatr Rev*. 2014;35(11):476-86. doi: 10.1542/pir.35-11-476.
6. Sowho M, Amatoury J, Kirkness JP, Patil SP. *Sleep and respiratory physiology in adults*. *Clin Chest Med*. 2014;35(3):469-81. doi: 10.1016/j.ccm.2014.06.002.
7. Hegewald MJ, Crapo RO. *Respiratory physiology in pregnancy*. *Clin Chest Med*. 2011;32(1):1-13. doi: 10.1016/j.ccm.2010.11.001.
8. Sebastian JC. *Respiratory physiology and pulmonary complications in obesity*. *Best Pract Res Clin Endocrinol Metab*. 2013;27(2):157-61. doi: 10.1016/j.beem.2013.04.014.
9. Sandberg C, Naylor J. *Respiratory physiology at altitude*. *J R Army Med Corps*. 2011;157(1):29-32. doi: 10.1136/jramc-157-01-05.
10. Hughes JM. *Assessing gas exchange*. *Chron Respir Dis*. 2007;4(4):205-14. doi: 10.1177/1479972307084446.
11. Cettolo V, Francescato MP. *Assessing breath-by-breath alveolar gas exchange: is the contiguity in time of breaths mandatory?* *Eur J Appl Physiol*. 2018;118(6):1119-30. doi: 10.1007/s00421-018-3842-y.
12. Schäffer T. *Respiratory physiology in sleep and wakefulness*. *Handb Clin Neurol*. 2011;98:371-81. doi: 10.1016/B978-0-444-52006-7.00024-1.
13. Friedman ML, Nitu ME. *Acute Respiratory Failure in Children*. *Pediatr Ann*. 2018;47(7):e268-e273. doi: 10.3928/19382359-20180625-01.
14. Lamba TS, Sharara RS, Singh AC, Balaan M. *Pathophysiology and Classification of Respiratory Failure*. *Crit Care Nurs Q*. 2016;39(2):85-93. doi: 10.1097/CNQ.0000000000000102.
15. Yeo EJ. *Hypoxia and aging*. *Exp Mol Med*. 2019;51(6):1-15. Published 2019 Jun 20. doi: 10.1038/s12276-019-0233-3.
16. Hanley ME, Bone RC. *Acute respiratory failure. Pathophysiology, causes, and clinical manifestations*. *Postgrad Med*. 1986;79(1):166-76. doi: 10.1080/00325481.1986.11699244.
17. Markou NK, Myrianthefs PM, Baltopoulos GJ. *Respiratory failure: an overview*. *Crit Care Nurs Q*. 2004;27(4):353-79. doi: 10.1097/00002727-200410000-00006.
18. Roussos C, Koutsoukou A. *Respiratory failure*. *Eur Respir J Suppl*. 2003;47:3s-14s. doi: 10.1183/09031936.03.00038503.
19. Adler D, Janssens JP. *The Pathophysiology of Respiratory Failure: Control of Breathing, Respiratory Load, and Muscle Capacity*. *Respiration*. 2019;97(2):93-104. doi: 10.1159/000494063.
20. Miller PE, van Diepen S, Ahmad T. *Acute Decompensated Heart Failure Complicated by Respiratory Failure*. *Circ Heart Fail*. 2019;12(5):e006013. doi: 10.1161/CIRCHEARTFAILURE.119.006013.
21. Khan FA, Chitkara RK. *Complications of acute respiratory failure*. *Postgrad Med*. 1986;79(1):205-14. doi: 10.1080/00325481.1986.11699247.
22. McDonald CF, Blyth CM, Lazarus MD, Marschner I, Barter CE. *Exertional oxygen of limited benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia*. *Am J Respir Crit Care Med*. 1995;152(5 Pt 1):1616-9. doi: 10.1164/ajrccm.152.5.7582304.
23. Eaton T, Garrett JE, Young P, Fergusson W, Kolbe J, Rudkin S, et al. *Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study*. *Eur Respir J*. 2002;20(2):306-312. doi: 10.1183/09031936.02.00301002.
24. Khor YH, Renzoni EA, Visca D, McDonald CF, Goh NSL. *Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns*. *ERJ Open Res*. 2019;5(3):00118-2019. doi: 10.1183/23120541.00118-2019.
25. Zieliński J. *Long-term oxygen therapy in conditions other than chronic obstructive pulmonary disease*. *Respir Care*. 2000;45(2):172-7.
26. Sandoval J, Aguirre JS, Pulido T, et al. *Nocturnal oxygen therapy in patients with the Eisenmenger syndrome*. *Am J Respir Crit Care Med*. 2001;164(9):1682-7. doi: 10.1164/ajrccm.164.9.2106076.
27. Moran F, Bradley JM, Piper AJ. *Non-invasive ventilation for cystic fibrosis*. *Cochrane Database Syst Rev*. 2017;2(2):CD002769. doi: 10.1002/14651858.CD002769.pub5.
28. Arias MA, García-Río F, Alonso-Fernández A, Sánchez AM. *[Sleep apnea-hypopnea syndromes and heart failure]*. *Rev Esp Cardiol*. 2007;60(4):415-27.
29. Luna Paredes MC, Asensio de la Cruz O, Cortell Aznar I, Martínez Carrasco MC, Barrio Gómez de Agüero MI, Pérez Ruiz E, et al. *[Oxygen therapy in acute and chronic conditions: Indications, oxygen systems, assessment and follow-up]*. *An Pediatr (Barc)*. 2009;71(2):161-74. doi: 10.1016/j.anpedi.2009.05.012.
30. Barjaktarevic I, Cooper CB. *Supplemental Oxygen Therapy for Patients with Chronic Obstructive Pulmonary Disease*. *Semin Respir Crit Care Med*. 2015;36(4):552-66. doi: 10.1055/s-0035-1556058.
31. Balfour-Lynn IM, Primhak RA, Shaw BN. *Home oxygen for children: who, how and when?* *Thorax*. 2005;60(1):76-81. doi: 10.1136/thx.2004.031211.
32. Kallstrom TJ; American Association for Respiratory Care (AARC). *AARC Clinical Practice Guideline: oxygen therapy for adults in the acute care facility--2002 revision & update*. *Respir Care*. 2002;47(6):717-20.
33. Pilar-Orive FJ, López-Fernández YM. *Oxigenoterapia de alto flujo*. *An Pediatr Contin*. 2014;12(1):25-9. doi: 10.1016/S1696-2818(14)70163-5.
34. MacIntyre NR. *Supporting oxygenation in acute respiratory failure*. *Respir Care*. 2013;58(1):142-50. doi: 10.4187/respcare.02087.
35. Gotera C, Díaz Lobato S, Pinto T, Winck JC. *Clinical evidence on high flow oxygen therapy and active humidification in adults*. *Rev Port Pneumol*. 2013;19(5):217-27. doi: 10.1016/j.rppneu.2013.03.005.